Literature DB >> 16831481

PEG conjugated VEGF siRNA for anti-angiogenic gene therapy.

Sun Hwa Kim1, Ji Hoon Jeong, Soo Hyun Lee, Sung Wan Kim, Tae Gwan Park.   

Abstract

A novel siRNA delivery system based on polyelectrolyte complex (PEC) micelles was introduced in this study. Vascular endothelial growth factor (VEGF) siRNA was conjugated to poly(ethylene glycol) (PEG) via a disulfide linkage (siRNA-PEG). The siRNA-PEG conjugate could form PEC micelles by interacting with cationic polyethylenimine (PEI) as a core forming agent. The VEGF siRNA-PEG/PEI PEC micelles showed greater stability than naked VEGF siRNA against enzymatic degradation. Under a reductive condition similar to cytosolic environment, an intact form of siRNA was released from the siRNA-PEG conjugate by cleavage of the disulfide linkage. The VEGF siRNA-PEG/PEI PEC micelles effectively silenced VEGF gene expression in prostate carcinoma cells (PC-3) up to 96.5% under an optimized formulation condition. They also showed a far superior VEGF gene silencing effect than VEGF siRNA/PEI complexes even in the presence of serum. This study suggests that the siRNA delivery system using VEGF siRNA-PEG/PEI PEC micelles could be potentially applied to RNAi-based anti-angiogenic treatment of cancer in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831481     DOI: 10.1016/j.jconrel.2006.05.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  52 in total

1.  Bioreducible polymers for gene delivery.

Authors:  Tae-Il Kim; Sung Wan Kim
Journal:  React Funct Polym       Date:  2011-03-01       Impact factor: 3.975

2.  Elimination pathways of systemically delivered siRNA.

Authors:  Yuanyu Huang; Junmei Hong; Shuquan Zheng; Yi Ding; Shutao Guo; Hongyan Zhang; Xiuqin Zhang; Quan Du; Zicai Liang
Journal:  Mol Ther       Date:  2010-11-30       Impact factor: 11.454

Review 3.  Chemical modification: the key to clinical application of RNA interference?

Authors:  David R Corey
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

4.  VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine).

Authors:  Sun Hwa Kim; Ji Hoon Jeong; Tae-il Kim; Sung Wan Kim; David A Bull
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

5.  Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo.

Authors:  S-T Chou; Q Leng; P Scaria; M Woodle; A J Mixson
Journal:  Cancer Gene Ther       Date:  2011-08-05       Impact factor: 5.987

6.  Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery.

Authors:  Oleh Taratula; Olga B Garbuzenko; Paul Kirkpatrick; Ipsit Pandya; Ronak Savla; Vitaly P Pozharov; Huixin He; Tamara Minko
Journal:  J Control Release       Date:  2009-06-28       Impact factor: 9.776

Review 7.  Self-assembled and nanostructured siRNA delivery systems.

Authors:  Ji Hoon Jeong; Tae Gwan Park; Sun Hwa Kim
Journal:  Pharm Res       Date:  2011-03-18       Impact factor: 4.200

Review 8.  Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction.

Authors:  James W Yockman; Andrew Kastenmeier; Harold M Erickson; Jonathan G Brumbach; Matthew G Whitten; Aida Albanil; Dean Y Li; Sung Wan Kim; David A Bull
Journal:  J Control Release       Date:  2008-07-06       Impact factor: 9.776

9.  Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMA-s-APMA) copolymers.

Authors:  Adam W York; Faqing Huang; Charles L McCormick
Journal:  Biomacromolecules       Date:  2010-02-08       Impact factor: 6.988

10.  Reductively Responsive Hydrogel Nanoparticles with Uniform Size, Shape, and Tunable Composition for Systemic siRNA Delivery in Vivo.

Authors:  Da Ma; Shaomin Tian; Jeremy Baryza; J Christopher Luft; Joseph M DeSimone
Journal:  Mol Pharm       Date:  2015-09-04       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.